Drugs / E. coli Nissle
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT02144948 | Aug 2014 → Jan 2016 | type 2 diabetes mellitus | GWT-TUD GmbH | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT04608851 | Jan 2021 → Dec 2024 | bacterial urinary tract infection | University of Oulu | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | E. coli Nissle | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04608851 ↗ |
| Route | Oral | “E.-coli-Nissle (Mutaflor), oral suspension” NCT02144948 ↗ |